Visceral leishmaniosis is one of largest parasitic killers in the world, which is annually responsible for more than 200,000 infections worldwide (
1). Fever, massive hepatomegaly, and splenomegaly are the most typical symptoms of the disease. The disease usually appears two to six months following infection (
2). Without proper treatment the mortality rate for kala-azar is close to 100% (
3).
Less invasive diagnostic methods are demonstration of specific antibodies, antigens, or parasite DNA in peripheral blood specimens (
4). The direct agglutination test (DAT) has high sensitivity but relatively low specificity (
5). The recombinant kinesin antigen (rK39) is a useful antigen in enzyme-linked immunosorbent assay (ELISA), also available in strip format as a rapid test (
6). The direct agglutination test (DAT) requires less equipment than ELISA, thus, it is useful in developing settings (
7).
The gold standard for the diagnosis of visceral leishmaniosis is the demonstration of parasite in tissue (usually bone marrow or spleen) (
8). Bone marrow aspirates are generally safer than splenic aspirates and the sensitivity of bone marrow smear is about 60 to 85%.